Rakovina Therapeutics IncOTC Pink - Current Information:RKVTFView on Canadian Exchange
- LAST PRICE0.0600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
May 30, 2024
Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update, from 5:52PM ET on Thursday May 30, 2024 by Dow Jones
5:52PM ET on Thursday May 30, 2024 by Dow Jones
May 24, 2024
May 23, 2024
Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement, from 7:30AM ET on Thursday May 23, 2024 by Dow Jones
7:30AM ET on Thursday May 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rakovina Therapeutics Inc | 7.7M | 0.0x | --- |
Company Information
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Company’s research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
Contact Information
- Headquarters
- 105 - 1008 Beach AvenueVancouver, BC, Canada V6E 1T7
- Phone
- 604-619-0225
- Fax
- 604-980-6264
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.04 |
Book Value | $0.05 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
